Isofol initiates preclinical evaluation of arfolitixorin with Oncosyne AS
Gothenburg, Sweden, April 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has initiated a preclinical research collaboration with the Norwegian biotech company Oncosyne AS, to evaluate the effect of the drug candidate arfolitixorin in different doses combined with the cancer drug 5-FU, among others. This is an important step in the company´s previously communicated strategy to re-evaluate possible future tracks for arfolitixorin and to maximize the opportunities to take the drug candidate further toward potential market approval.
The information in the press release is intended for investors.
Isofol, together with external experts, is conducting an extensive analysis of the data from the clinical phase III study, AGENT. In the study, arfolitixorin did not meet its goals and the study was terminated in 2022. The initial conclusions from the analysis indicate that the dose of arfolitixorin may have been too low to allow a fair comparison with the control group and that the substance may not have been administrated optimally. Arfolitixorin's safety profile was a prioritized part of the analysis, and the company has not found any obstacles to proceed with the development of the drug candidate.
Based on the initial analysis of data from the AGENT study, Isofol intends to evaluate several doses of arfolitixorin in combination with 5-FU as well as other possible treatments, within a research collaboration with the Norwegian biotech company Oncosyne.
Oncosyne AS has developed a technology platform for preclinical testing in functional precision oncology, based on drug screening of the patient’s own cancer cells. The technology can be used in several stages of drug development from functional evaluation of drug activity to selection of patients for clinical trials.
” Initial outcomes from the comprehensive analysis of phase III data conducted in collaboration with leading external experts provide support for initiating a preclinical evaluation of the drug candidate. Oncosyne has developed a technology platform that quickly and cost-effectively can provide an answer to whether a different dosage regiment could strengthen the future potential of arfolitixorin,” says Thomas Andersson, CEO of Isofol.
For more information, please contact
Isofol Medical AB (publ)
Thomas Andersson, Chief Executive Officer
E-mail: thomas.andersson@isofolmedical.com
Phone: +46 (0) 709 44 00 93
The information was submitted for publication, through the agency of the contact person set out above, at 16:20 CEST, on April 28, 2023.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Tags: